The Joint Corp (JYNT)vsEli Lilly and Company (LLY)
JYNT
The Joint Corp
$8.29
+0.73%
HEALTHCARE · Cap: $118.18M
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 127463% more annual revenue ($72.25B vs $56.64M). LLY leads profitability with a 35.0% profit margin vs 5.7%. LLY appears more attractively valued with a PEG of 1.45. LLY earns a higher WallStSmart Score of 78/100 (B+).
JYNT
Hold47
out of 100
Grade: D+
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Earnings expanding 43.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
5.7% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JYNT
The strongest argument for JYNT centers on Return on Equity, Debt/Equity, EPS Growth. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : JYNT
The primary concerns for JYNT are Market Cap, Profit Margin, PEG Ratio. A P/E of 92.1x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
JYNT profiles as a value stock while LLY is a growth play — different risk/reward profiles.
JYNT carries more volatility with a beta of 1.10 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 47/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Joint Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?